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Abstract
Vascular endothelial growth factor receptor-2 (VEGFR-2); a cell surface receptor for 
vascular endothelial growth factors, is a key pharmacological target involved in the cell 
proliferation/angiogenesis. It has been revealed that VEGFR-2 induces proliferation through 
activation of the extracellular signal-regulated kinases pathway. In this regard, targeting the 
VEGFR-2 has been considered as an efficient route to develop anti-tumor agents. Motesanib is 
a small-molecule antagonist of VEGFR-1, 2, and 3 (IC50s; 2 nM, 3 nM, 6 nM, respectively). 
It is an experimental drug candidate undergoing clinical trials against some types of cancer. In 
the present study, Motesanib (AMG 706) was evaluated in terms of its binding energies with 
individual amino acids of VEGFR-2 active site (amino acid decomposition analysis). For this 
purpose, functional B3LYP associated with split valence basis set using polarization functions 
(Def2-SVP) was used. Comparative conformational analysis of the ligand in optimized and 
crystallographic states revealed that Motesanib does not necessarily bind to the VEGFR-2 
active site in its minimum energy conformer.
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Introduction
Vascular endothelial growth factors (VEGFs) 
bind to three structurally related receptor 
tyrosine kinases; VEGFR-1, VEGFR-2, and 
VEGFR-3. A number of coreceptors such as 
neuropilins that lack intrinsic catalytic activity 
bind to VEGF and also modulate the effect of 
the VEGFRs (1). VEGFRs have a high degree of 
homology within the kinase domain; however, 
their signaling properties greatly differ (1). 
VEGFR-2 is the major mediator of responses 
in endothelial cells and it is considered to be a 
principal signal transducer in angiogenesis (2). 
Vascular endothelial growth factor receptor 2 
(VEGFR-2) is a cell surface receptor for VEGFs 
(3, 4). VEGF signaling pathway has been well 
demonstrated to induce angiogenesis during 
tumor development (5, 3). Vascular endothelial 
growth factor (VEGF) has been found to be a 
major driver of tumor angiogenesis leading to 
efforts in development of novel therapeutics 
aimed at inhibiting its activity. It is generally 
accepted that the destructive growth of tumors 
and their metastases is highly depended on 
angiogenesis (6).
Anti-VEGF therapy has been regarded as a 
prominent choice for the management of several 
human malignancies. The vast majority of solid 
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comprise mainly two categories; ligand- 
based and structure-based methods. Within 
this scenario, theoretical methods based on 
density- functional theory (DFT) are going to 
play an increasingly important role in many 
applications of computational chemistry to 
drug discovery (27-29). One of the mostly used 
DFT methods is Becke three-parameter Lee-
Yang-Parr (B3LYP) hybrid density functional 
theory (30). This technique has been applied 
for conformational analysis of antiangiogenic 
agents such as Motesanib (31). Estimating the 
proportion of individual amino acid-ligand 
interaction energies in total binding energy 
would be a very useful trend in pharmacophore 
discernment and development (Amino acid 
decomposition analysis). No such report could 
be found for Motesanib with VEGFR-2. 
In continuation to our interest in developing 
new cytotoxic agents (32), we aimed to 
determine the binding pose and binding 
energies of Motesanib in VEGFR-2 active site. 
For this purpose, DFT calculations at the level 
of B3LYP/Def2-SVP were used to estimate 
the individual amino acid-ligand interaction 
energies. Furthermore; conformational analysis 
of Motesanib was performed at the same level 
of theory to determine the torsional deviation 
from minimum energy state upon binding to the 
receptor.
Experimental
Computational section
X-ray crystallographic structure of VEGFR-2 
with its cognate ligand (AMG 706) was 
downloaded from Brook Haven Protein databank 
(PDB code: 3EFL, www.rcsb.org). All the pre-
processing procedure for ligand and receptor 
crystallographic files were done within WHAT 
IF server (European Molecular Laboratory 
Heidelberg, Germany). All hydrogens were 
properly added to the receptor PDB file using 
What if server. All computational DFT studies 
were performed using functional B3LYP 
associated with split valence basis set using 
polarization functions (Def2-SVP) (33).
The evaluated amino acid residues in ab 
initio study (Leu889, Ala866, Lys868, Glu885, 
Val899, Val916, Cys919, Leu1035, Asp1046) 
tumors are involved with VEGF overexpression 
(7). In this regard, chemical agents with the 
inhibitory activity on angiogenesis may be 
focused as a workable treatment options 
for patients involved with solid tumors (8). 
Inhibition of VEGF has been reported to 
significantly suppress tumor angiogenesis in 
mouse tumor models (9). The angiogenesis 
process of solid tumors may be avoided due to 
the inhibition of the tyrosine kinase VEGFR-2 
signaling pathway. In this way required blood 
flow for developing tumor would decrease 
dramatically and even the growth will stopped 
because of lack of nutrient and growth factors 
supported by freshly forming vessels (10,11). 
Hence, anti-tumor drug development targeting 
VEGFR-2 signalling pathway has been recently 
highlighted as an important way in the clinical 
trials (12). 
A number of structurally diverse small 
molecule VEGFR-2 inhibitors such as 
indolin-2-ones, phthalazines, quinolinones, 
imidazopyridines, benzimidazoles,quinoline 
amides, pyridines and quinazolines have 
been introduced in the literature (13-19). 
In a typical lead/drug discovery protocol, 
potential candidate molecules may suffer from 
undesirable properties in their pharmacokinetic 
and pharmacodynamic profiles. Structure-
based drug design has been considered as 
one of the major strategies in achieving 
potential drug candidates (20,21). Motesanib 
(N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-
yl)-2-((pyridin-4-ylmethyl)amino)pyridine-3-
carboxamide) is an experimental drug candidate 
which has been exhibited antagonistic activity 
for VEGFR-2 (22). Clinical trials on potential 
beneficial effects of Motesanib against some 
types of cancers are being actively pursued. 
Results showed that Motesanib inhibited 
VEGFR-1, 2, and 3 with IC50 values of 2, 3 
and 6 nM respectively (23-25). 
In lead-drug development strategies, 
combination of experimental methods with 
computer aided molecular design (CAMD) 
techniques is essential for the development 
of new drugs aimed at new targets, and 
thus for medicinal chemistry (26). Various 
computational chemistry methods are in 
hand for running CAMD. These methods 
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were chosen according to the information 
from crystallographic data (34). The proposed 
interaction profile could be found in Brook 
Haven Protein databank. All amino acids were 
considered in their real electrostatic state. 
For each residue under study, N-terminal was 
acetylated and C-terminal was methyl amidated 
to mimic the original electron density. All 
conformational and configurational features 
were the same as the X-ray structure. However 
the positions of hydrogen bonds are not clearly 
recognized in a typical X-ray crystallographic 
file and this restriction persuaded us to further 
optimize the heavy atom-hydrogen bonds using 
constrained optimization method (heavy atom 
fixing approximation).
All ligand-receptor interaction energies were 
estimated by B3LYP/ Def2-SVP method. The 
whole calculations were done with the ORCA 
quantum chemistry package (30). The optimized 
structures were visualized by Visual Molecular 
Dynamics program (VMD) (35). 
Results and Discussion
Ab initio study of ligand-receptor interactions
To obtain a binding profile between a 
Motesanib and VEGFR-2 active site, relevant 
amino acids were chosen on the basis of 
information from Protein Data Bank (PDB). The 
representation of the Motesanib structure in the 
active site of VEGFR-2 was further confirmed 
via schematic 2D interaction profile generated 
by LIGPLOT Figure 1.
The directionality of hydrogen bonds 
including optimum distances and angles supports 
efficient interactions with receptor. Bearing this 
in mind, the optimization process was done with 
the same basis set to obtain the exact geometry 
of H-bonds. The related data are summarized 
in Table 1. Hydrogen bond geometries were 
described as H-donor-acceptor angles. It should 
be noted that hydrogen bond lengths were 
obtained considering H-acceptor distances.
Ligand-residue binding energies (ΔEb) were 
Figure 1. 2D representation of ligand-receptor interactions for Motesanib in VEGFR-2 active site.
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calculated using the following equation: 
ΔEb = ELR - EL - ER                        Equation (1)
 
ELR stands for residue-ligand interaction 
energy, ER and EL indicate the electronic energies 
for residues and ligand, respectively. Individual 
ligand-residue binding energies are shown in 
Figure 2.
Lipophilic contacts are a function of 
orientation, constant/induced dipole moments 
and distance (36). Attractive hydrophobic 
interaction was made between AMG 706 and 
Ala866 residue (-0.56 cal/mol). Regarding 
the obtained results, one may assume that 
electrostatic hydrogen bonding interactions may 
have significant contribution to total binding 
energy between AMG 709 and receptor. For 
Leu889, Val899, Val916 and Leu1035 the 
positive binding energies might be related to 
an inappropriate orientation of ligand in the 
active site of receptor (crystallographic state). It 
should be noticed that molecular dynamic may 
assist in balancing these close contacts which 
are responsible for repulsive interactions with 
receptor.
The role of cation-pi interaction as a force 
for molecular recognition in biological media 
has been revealed via studies on model systems 
and the analysis of biological macromolecular 
structures (36). In Lys868 the quaternary amine 
moiety might be responsible for observed 
cation-π interaction with central pyridine ring 
of AMG 709 (-3.93 kcal/mol). Binding pose 
of the ligand revealed that nitrogenous cation 
centered on the top of the π face of pyridine 
ring (Figure 3). Our estimated energy for the 
associated cation-π interaction correlated well 
with previously reported data (37), but might 
be less than accepted values (38). This energy 
difference might be attributed to the existence 
of pyridine lone pair. In pyridine, the lone pair 
does not participate in aromaticity and thus 
electronegativity of the heteroatom wins out and 
Amino acid Optimized hydrogen bond distances (Å) state hydrogen bond angle (degree)
Glu885 2.11 11.66
Asp1046 2.04 9.60
Cys919 2.19 5.21
Table 1. Hydrogen-bond analysis of cognate inhibitor (Motesanib) with VEGFR-2 residues.
Figure 2. Individual residue-ligand interaction energies for Motesanib and VEGFR-2.
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weakens the cation-π binding ability.
The deprotonated Glu885 is the most 
significant residue for enzyme-inhibitor 
interactions due to the strong hydrogen bond 
with the amide NH in AMG 706. Typical 
charge-assisted hydrogen bond between Glu885 
and amide NH was found to be supported by 
significant binding energy of -26.82 kcal/mol. 
Another important H-bond between Asp1046 
and amide oxygen was associated with -12.96 
kcal/mol interaction energy. In the case of 
Cys919 residue, the observed binding energy 
was estimated to be -9.06 kcal/mol. In fact 
hydrogen bonding interaction with Cys919 from 
H-donor group of the inhibitor is the key feature 
of VEGFR inhibitors (39).
In ligand-receptor interaction, stereoelectronic 
effects are prominent in determining 
complementary potential electrostatic surfaces. 
Ligand electronic structure may address its 
proper orientation in the enzyme active site and 
potent inhibition would be expected regarding 
proper fitness of the ligand and electronic 
surfaces of the active site. 
Mulliken partial electronic charges were 
assigned to the constituent atoms of compound 
AMG 709 (Figure 4) (40). It should be noted 
that atoms participated in key bindings with 
Asp1046, Glu885 (charge-assisted interactions) 
and Cyc919 residues possessed relatively 
negative electronic charges.
Comparative conformational analysis
We decided to quantify the conformational 
divergence of AMG 709 upon binding to 
the VEGFR-2 active site. For this purpose, 
aqueous biological medium was modeled in 
our ligand optimization procedure. Estimated 
binding energies for compound AMG 709 may 
be a direct outcome of varied internal energies 
of ligand in its protein bound and free states 
within biological media (ΔEinstability). ΔEinst. can 
Figure 3. 3D representation of cation-π interaction between Lys868 and Motesanib.
Figure 4. Mulliken partial charge distribution for Motesanib 
heavy atoms.
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may account for the participation of solvation 
in binding profile. In the light of the above 
information, solvation energy of Motesanib 
molecule needs must be taken into account 
for the correlation of ΔEtb and ΔGb terms. This 
result might further demonstrate the important 
role of solvent molecules in determining final 
free binding energy of ligand-receptor system. 
The estimated conformational change of 
ligand structure upon binding to the receptor 
was evaluated in a more detailed way via 
performing comparative conformational 
analysis of the molecular geometries. For this 
purpose, optimized 3D structure of AMG 709 
was obtained by DFT calculations via B3LYP 
method in association with split valence basis 
set using polarization functions (Def2-SVP). 
Frequency calculation with same basis set was 
performed to confirm the optimized structure. 
All frequencies were real and no imaginary 
frequency was seen. The resulted geometric 
poses in terms of bond lengths and dihedral 
angles are summarized in Tables 2 and 3. It 
should be noticed that due to the uncertainty 
in the delicate position of hydrogen atoms in 
crystallographic file, associated data have not 
been shown in Tables. We found that all the 
calculated bond lengths of the DFT optimized 
structure were in adaptable correlation with the 
crystallographic data.
The varied dihedral angles between 
optimized and crystallographic ligand poses 
would be expected upon binding to the 
receptor active site. AMG 709 adapted some 
torsional distortions to get proper oriented 
pharmacophoric points. These well-oriented 
functional groups might be critical in achieving 
optimum key interactions with the residues of 
the VEGFR-2 active site. 
Regarding the data in Table 3, some 
relatively significant angular deviations may 
be noticed. The observed rotation of C15-C16 
bond (Figure 5) let to the noticeable change in 
C8(13)-C15-N16-C18 dihedral angel (Table 3). 
This conformational distortion occurred at the 
amide linker.
All the mentioned conformational changes 
occurred in the structural moieties participated 
in interactions with key amino acids of 
VEGFR-2 active site (Figure 1).
be defined as an energy difference for ligand in 
its free and protein bound states within aqueous 
medium. ΔEinst. needs to be considered in order 
to adjust obtained binding energies. Water was 
selected as a biological medium for this purpose. 
For the purpose of calculating ΔEinst., 
optimum structural conformation of compound 
AMG 709 was obtained in water and relevant 
energy was assigned to the free state . In the next 
step, the energy of receptor bound ligand was 
obtained in the crystallographic state. ΔEinst. may 
be well related with the free energy of binding 
via following equations:
ΔGb = ΔHb - TΔSb                                                   Equation (2)
ΔHb = ΔEt - PΔV ≈ ΔEtb                              Equation (3)
ΔEtb = ΔEb + ΔEinst                         Equation (4)
Higher ΔEinst. values support more positive 
total binding energies (ΔEtb) consequently 
leading to weaker ligand-receptor interactions 
in terms of free binding energies (ΔGb). Our 
calculations showed that AMG 709 tolerated 
8.91 kcal/mol instability to gain the appropriate 
conformation in binding to the receptor. Based 
on the obtained results, ΔEtb was found to be 
-40.36 kcal/mol. Two conformational poses of 
the ligand are depicted in Figure 5.
However the difference between ΔEtb and 
ΔGb values associated with relevant ligand 
Figure 5. Conformational structure deviation of Motesanib in 
VEDFR-2 active site (up), and optimized conformer (down).
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Bond
Bond length (Å)
Bond
Bond length (Å)
Crystallographic state Optimized state Crystallographic state Optimized state
C1-C2 1.530 1.5453 C18-C20 1.532 1.4925
C1-H42 - 1.0964 O19-H30 - 1.8692
C1-H43 - 1.0946 C20-C21 1.389 1.3977
C1-H44 - 1.0939 C20-C28 1.393 1.4381
C2-C3 1.530 1.5346 C21-H22 - 1.0868
C2-C4 1.528 1.5597 C21-C23 1.391 1.3916
C2-C10 1.530 1.5258 C23-H24 - 1.0837
C3-H45 - 1.0943 C23-C25 1.391 1.3944
C3-H46 - 1.0951 C25-H26 - 1.0892
C3-H47 - 1.0962 C25-N27 1.323 1.3307
C4-N5 1.471 1.4736 N27-C28 1.343 1.3486
C4-H48 - 1.0947 C28-N29 1.332 1.3606
C4-H49 - 1.1017 N29-H30 - 1.016
N5-H6 - 1.0121 N29-C31 1.470 1.446
N5-C7 1.333 1.3981 C31-C32 1.531 1.5218
C7-C8 1.393 1.39 C31-H50 - 1.0978
C7-C10 1.395 1.4056 C31-H51 - 1.0926
C8-H9 - 1.0879 C32-C33 1.392 1.3951
C8-C15 1.393 1.4092 C32-C40 1.392 1.4001
C10-C11 1.392 1.3851 C33-H34 - 1.0848
C11-H12 - 1.087 C33-C35 1.390 1.3966
C11-C13 1.391 1.4021 C35-H36 - 1.0889
C13-H14 - 1.079 C35-N37 1.323 1.3376
C13-C15 1.394 1.4019 N37-C38 1.323 1.3408
C15-N16 1.330 1.4145 C38-H39 - 1.0888
N16-H17 - 1.0084 C38-C40 1.391 1.3922
N16-C18 1.331 1.3731 C40-H41 - 1.0872
C18-O19 1.230 1.2385
Table 2. Bond lengths of Motesanib in the optimized and crystallographic (VEGFR-2, PDB code: 3EFL) conformers.
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Dihedral angle
Angle (degree)
Dihedral angle
Angle (degree)
Crystallographic state Optimized state Crystallographic state Optimized state
H42-C1-C2-C3 - 56.282 C8-C15-N16-C18 -134.086 -178.173
H42-C1-C2-C4 - -67.538 C13-C15-N16-H17 - 176.423
H42-C1-C2-C10 - -177.279 C13-C15-N16-C18 52.015 2.511
H43-C1-C2-C3 - -63.575 C15-N16-C18-O19 1.241 3.4426
H43-C1-C2-C4 - 172.605 C15-N16-C18-C20 -178.813 -177.293
H43-C1-C2-C10 - 62.862 H17-N16-C18-O19 - -170.398
H44-C1-C2-C3 - 176.567 H17-N16-C18-C20 - 8.8673
H44-C1-C2-C4 - 52.747 N16-C18-C20-C21 15.753 23.472
H44-C1-C2-C10 - -56.995 N16-C18-C20-C28 -166.812 -158.203
C1-C2-C3-H45 - 178.045 O19-C18-C20-C21 -164.298 -157.260
C1-C2-C3-H46 - 57.839 O19-C18-C20-C28 13.136 21.065
C1-C2-C3-H47 - -61.358 C18-C20-C21-H22 - 3.080
C4-C2-C3-H45 - -59.025 C18-C20-C21-C23 177.361 -178.980
C4-C2-C3-H46 - -179.231 C28-C20-C21-H22 - -175.305
C4-C2-C3-H47 - 61.572 C28-C20-C21-C23 -0.114 2.635
C10-C2-C3-H45 - 53.925 C18-C20-C28-N27 -177.196 177.765
C10-C2-C3-H46 - -66.282 C18-C20-C28-N29 2.607 -1.169
C10-C2-C3-H47 - 174.522 C21-C20-C28-N27 0.280 -3.815
C1-C2-C4-N5 -101.759 -88.860 C21-C20-C28-N29 -179.918 177.251
C1-C2-C4-H48 - 31.355 C20-C21-C23-H24 - -179.516
C1-C2-C4-H49 - 151.806 C20-C21-C23-C25 -0.052 -0.028
C3-C2-C4-N5 133.531 148.232 H22-C21-C23-H24 - -1.559
C3-C2-C4-H48 - -91.553 H22-C21-C23-C25 179.979 177.928
C3-C2-C4-H49 - 28.898 C21-C23-C25-H26 - 179.086
C10-C2-C4-N5 15.886 27.029 C21-C23-C25-N27 0.058 -1.787
C10-C2-C4-H48 - 147.243 H24-C23-C25-H26 - -1.424
C10-C2-C4-H49 - -92.305 H24-C23-C25-N27 - 177.703
C1-C2-C10-C7 102.711 98.816 C23-C25-N27-C28 0.113 0.682
C1-C2-C10-C11 -74.692 -78.169 H26-C25-N27-C28 - 179.846
C3-C2-C10-C7 -133.134 -136.914 C25-N27-C28-C20 -0.285 2.216
C3-C2-C10-C11 49.463 46.101 C25-N27-C28-N29 179.914 -178.813
C4-C2-C10-C7 -15.307 -17.309 C20-C28-N29-H30 - -8.165
C4-C2-C10-C11 167.290 165.705 C20-C28-N29-C31 171.865 -177.332
C2-C4-N5-H6 - -161.533 N27-C28-N29-H30 - 172.857
C2-C4-N5-C7 -12.375 -28.598 N27-C28-N29-C31 -8.334 3.690
H48-C4-N5-H6 - 77.305 C28-N29-C31-C32 94.086 102.346
H48-C4-N5-C7 - -149.760 C28-N29-C31-H50 - -135.519
H49-C4-N5-C6 - -43.223 C28-N29-C31-H51 - -19.574
H49-C4-N5-C7 - 89.712 H30-N29-C31-C32 - -66.239
C4-N5-C7-C8 -170.367 -163.627 H30-N29-C31-H50 - 55.896
C4-N5-C7-C10 2.573 18.132 H30-N29-C31-H51 - 171.841
H6-N5-C7-C8 - -31.016 N29-C31-C32-C33 5.187 -4.398
H6-N5-C7-C10 - 150.744 N29-C31-C32-C40 -173.633 175.611
Table 3. Dihedral angles of Motesanib in the optimized and crystallographic (VEGFR-2, PDB code: 3EFL) conformers.
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Dihedral angle
Angle (degree)
Dihedral angle
Angle (degree)
Crystallographic state Optimized state Crystallographic state Optimized state
N5-C7-C8-H9 - 2.343 H50-C31-C32-C33 - -126.654
N5-C7-C8-C15 171.649 -177.916 H50-C31-C32-C40 - 53.354
C10-C7-C8-H9 - -179.584 H51-C31-C32-C33 - 116.660
C10-C7-C8-C15 -0.751 0.156 H51-C31-C32-C40 - -63.331
N5-C7-C10-C2 8.568 0.493 C31-C32-C33-H34 - 0.520
N5-C7-C10-C11 -173.683 177.903 C31-C32-C33-C35 -178.533 -179.807
C8-C7-C10-C2 -177.684 -177.894 C40-C32-C33-H34 - -179.489
C8-C7-C10-C11 0.066 -0.484 C40-C32-C33-C35 0.297 0.184
C7-C8-C15-C13 1.044 -0.027 C31-C32-C40-C38 178.603 179.705
C7-C8-C15-N16 -172.919 -179.364 C31-C32-C40-H41 - -0.199
H9-C8-C15-C13 - 179.715 C33-C32-C40-C38 -0.223 -0.288
H9-C8-C15-N16 - 0.378 C33-C32-C40-H41 - 179.809
C2-C10-C11-H12 - -3.188 C32-C33-C35-H36 - -179.948
C2-C10-C11-C13 177.471 177.413 C32-C33-C35-N37 -0.201 0.009
C7-C10-C11-H12 - -179.917 H34-C33-C35-H36 - -0.274
C7-C10-C11-C13 0.316 0.684 H34-C33-C35-N37 - 179.683
C10-C11-C13-H14 - 179.731 C33-C35-N37-C38 0.036 -0.095
C10-C11-C13-C15 -0.019 -0.558 H36-C35-N37-C38 - 179.863
H12-C11-C13-H14 - 0.323 C35-N37-C38-H39 - -179.957
H12-C11-C13-C15 - -179.966 C35-N37-C38-C40 0.031 -0.018
C11-C13-C15-C8 -0.654 0.224 N37-C38-C40-C32 0.070 0.214
C11-C13-C15-N16 173.284 179.508 N37-C38-C40-H41 - -179.882
H14-C13-C15-C8 - 179.938 H39-C38-C40-C32 - -179.849
H14-C13-C15-N16 - -0.777 H39-C38-C40-H41 - 0.055
C8-C15-N16-H17 - -4.261
Table 3. (Continue).
Conclusion 
Amino acid decomposition analysis provided 
further insight into the effect of individual amino 
acid residues on Motesanib/VEGFR-2 binding 
profile. Such structure-based studies may serve 
as efficient analyzing tools in evaluating the 
pharmacophore models. Owing to the prominent 
role of electrostatic forces in initial ligand-
receptor interactions, charge-assisted H-bonds 
and cation-pi interactions need to be particularly 
attended. In the case of Cys919, the estimated 
binding energy could further confirm the role of 
this key amino acid in contribution to H-bond 
interactions reported for various VEGFR 
inhibitors. We could further demonstrate that 
Motesanib does not necessarily bind to the 
receptor in its optimum conformation state.
Acknowledgements
Financial supports of this project by research 
council of Shiraz University of Medical 
Sciences are acknowledged.
References
Rapisarda A and Melillo G. Role of the VEGF/VEGFR 
axis in cancer biology and therapy. Adv. Cancer Res. 
(2012) 114: 237-267.
Hicklin DJ and Ellis LM. Role of the vascular 
endothelial growth factor pathway in tumor growth and 
angiogenesis. J. Clin. Oncol. (2005) 23: 1011-1027.
Ferrara N, Gerber HP and LeCouter J. The biology of 
VEGF and its receptors. Nat. med. (2003) 9: 669-676.
Strawn LM, McMahon G, App H, Schreck R, Kuchler 
WR, Longhi MP, Hui TH, Tang C, Levitzki A and 
Gazit A. Flk-1 as a target for tumor growth inhibition. 
Cancer Res. (1996) 56: 3540-3545.
(1)
(2)
(3)
(4)
Ebadi A et al. / IJPR (2014), 12 (2): 405-415
414
Silva SR, Bowen KA, Rychahou PG, Jackson LN, 
Weiss HL, Lee EY, Townsend Jr CM and Evers BM. 
VEGFR 2 expression in carcinoid cancer cells and its 
role in tumor growth and metastasis. Int. J. CANCER. 
(2011) 128: 1045-1056.
Hanahan D and Folkman J. Patterns and emerging 
mechanisms of the angiogenic switch during 
tumorigenesis. Cell. (1996) 86: 353-364.
Dvorak HF. Vascular permeability factor/vascular 
endothelial growth factor: a critical cytokine in tumor 
angiogenesis and a potential target for diagnosis and 
therapy. J. Clin. Oncol. (2002) 20: 4368-4380.
Carmeliet P. Angiogenesis in life, disease and medicine. 
Nature (2005) 438: 932-936.
Ferrara N and Gerber HP. The role of vascular 
endothelial growth factor in angiogenesis. Acta. 
Haematol-Basel. (2000) 106: 148-156.
Peruzzi B and Bottaro DP. Targeting the c-Met 
signaling pathway in cancer. Clin. Cancer Res. (2006) 
12: 3657-3657.
Ferrara N. Vascular endothelial growth factor as a 
target for anticancer therapy. Oncologist. (2004) 9: 
2-10.
Holmes K, Roberts OL, Thomas AM and Cross 
MJ. Vascular endothelial growth factor receptor-2: 
structure, function, intracellular signalling and 
therapeutic inhibition. Cell. Signalling. (2007) 19: 
2003-2012.
Sun L, Tran N, Liang C, Hubbard S, Tang F, Lipson 
K, Schreck R, Zhou Y, McMahon G and Tang C. 
Identification of Substituted 3-[(4,5,6,7-Tetrahydro-
1H-indol-2-yl)methylene]- 1,3-dihydroindol-2-ones as 
Growth Factor Receptor Inhibitors for VEGF-R2 (Flk-
1/KDR), FGF-R1, and PDGF-Rβ Tyrosine Kinases. J. 
Med. Chem. (2000) 43: 2655-2663.
Bold G, Altmann KH, Frei J, Lang M, Manley PW, 
Traxler P, Wietfeld B, Bruggen J, Buchdunger E, 
Cozens R, Ferrari S, Furet P, Hofmann F, Artinybaron 
G, Mestan J, Rosel J, Sills M, Stover D, Acemoglu F, 
Boss E, Emmenegger R, Lasser L, Masso E, Roth R, 
Schlachter C and Vetterli W. New anilinophthalazines 
as potent and orally well absorbed inhibitors of the 
VEGF receptor tyrosine kinases useful as antagonists 
of tumor-driven angiogenesis. J. Med. Chem. (2000) 
43: 2310-2323.
Hennequin LF, Stokes ES, Thomas AP, Johnstone C, 
Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew 
J and Curwen JO. Novel 4-Anilinoquinazolines with 
C-7 Basic Side Chains:  Design and Structure Activity 
Relationship of a Series of Potent, Orally Active, 
VEGF Receptor Tyrosine Kinase Inhibitors. J. Med. 
Chem. (2002) 45: 1300-1312.
Bilodeau MT, Rodman LD, McGaughey GB, Coll KE, 
Koester TJ, Hoffman WF, Hungate RW, Kendall RL, 
McFall RC, Rickert KW, Rutledge RZ and Thomas 
KA. The discovery of N-(1,3-thiazol-2-yl)pyridin-2-
amines as potent inhibitors of KDR kinase. Bioorg. 
Med. Chem. Lett. (2004) 14: 2941-2945.
Bilodeau MT, Cunningham AM, Koester TJ, Ciecko PA, 
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
Coll KE, Huckle WR, Hungate RW, Kendall RL, McFall 
RC, Mao X, Rutledge RZ and Thomas KA. Synthesis 
and inhibitory activity of ubiquinone–acetogenin hybrid 
inhibitor with bovine mitochondrial complex I. Bioorg. 
Med. Chem. Lett. (2003) 13: 2385-2388.
Wu Z, Fraley ME, Bilodeau MT, Kaufman ML, Tasber 
ES, Balitza AE, Hartman GD, Coll KE, Rickert K, 
Shipman J, Shi B, Sepp-Lorenzino L and Thomas KA. 
Design and synthesis of 3,7-diarylimidazopyridines as 
inhibitors of the VEGF-receptor KDR. Bioorg. Med. 
Chem. Lett. (2004) 14: 909-912.
Fraley ME, Arrington KL, Buser CA, Ciecko PA, 
Coll KE, Fernandes C, Hartman GD, Hoffman WF, 
Lynch JJ, McFall RC, Rickert K, Singh R, Smith 
S, Thomas KA and Wong BK. Optimization of the 
indolyl quinolinone class of KDR (VEGFR-2) kinase 
inhibitors: effects of 5-amido- and 5-sulphonamido-
indolyl groups on pharmacokinetics and hERG 
binding. Bioorg. Med. Chem. Lett. (2004) 14: 351-355.
Anderson AC. Structure-based functional design of 
drugs: from target to lead compound. Method. Mol. 
Biol. (2012) 823: 359-366.
Bohacek RS, McMartin C and C GW. The art and 
practice of structure-based drug design: A molecular 
modeling perspective. Med. Res. Rev. (1996) 16: 3-50.
Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt 
L, Martins RG, Licitra L, Eschenberg MJ, Sun YN 
and Juan T. Motesanib diphosphate in progressive 
differentiated thyroid cancer. N. Engl. J. Med. (2008) 
359: 31-42.
Rosen LS, Kurzrock R, Mulay M, Vugt AV, Purdom 
M, Ng C, Silverman J, Koutsoukos A, Sun Y-N, Bass 
MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, 
Benjamin R and S HR. Safety, pharmacokinetics, and 
efficacy of AMG 706, an oral multikinase inhibitor, in 
patients with advanced solid tumors. J. Clin. Oncol. 
(2007) 25: 2369-2376.
Coxon A, Bush T, Saffran T, Kaufman S, Belmontes 
B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker 
A, Patel V, Kendall R, Radinsky R and Polverino A. 
Broad antitumor activity in breast cancer xenografts by 
motesanib,a highly selective, oral Inhibitor of vascular 
endothelial growth factor, platelet-derived growth 
factor, and kit receptors. Clin. Cancer Res. (2009) 15: 
110-118.
Sherman SI, Wirth LJ, Droz J-P, Hofmann M, Bastholt 
L, Martins RG, Licitra L, Eschenberg MJ, Sun Y-N, 
Juan T, Stepan DE and Schlumberger MJ. Motesanib 
diphosphate in progressive differentiated thyroid 
cancer. N. Engl. J. Med. (2008) 359: 31-42.
Razzaghi-Asl N, Ebadi A, Edraki N, Shahabipour S and 
Miri R. Fragment-based Binding Efficiency Indices 
in Bioactive Molecular Design: A Computational 
Approach to BACE-1 Inhibitors. Iran. J. Pharm. Res. 
(2013) 12: 423-436.
Vedani A, Zbinden P, Snyder JP and Greenidge PA. 
Pseudoreceptor Modeling: The Construction of Three-
Dimensional Receptor Surrogates. J. Am. Chem. Soc. 
(1995) 117: 4987-4994
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
“Molecular modeling of Motesanib”
415
This article is available online at http://www.ijpr.ir
Bissantz C, Folkers G and Rognan D. Protein-Based 
Virtual Screening of Chemical Databases. 1. Evaluation 
of Different Docking/Scoring Combinations. J. Med. 
Chem. (2000) 43: 4759-4767.
Kubinyi H. QSAR and 3D QSAR in drug design 
Part 1: methodology. Drug Discov. Today. (1997) 2: 
457-467.
Neese F ORCA – an ab initio, Density Functional 
and Semiempirical program package, Version 2.8.0 
University of Bonn (2011). 
Remko M, Boha´c A and Kova´cˇikova L. Molecular 
structure, pKa, lipophilicity, solubility, absorption, 
polar surface area, and blood brain barrier penetration 
of some antiangiogenic agents. Struct. Chem. (2011) 
22: 635-648.
Miri R, Firuzi O, Peymani P, Nazarian Z and Shafiee A. 
Synthesis and cytotoxicity study of new cyclopenta [b] 
quinoline-1, 8-dione derivatives. Iran. Pharm. J. Res. 
(2011) 3: 489-496.
Schaefer A, Horn H and Ahlrichs R. Property-
optimized Gaussian basis sets for molecular response 
calculations. J. Chem. Phys. (1992) 97: 2571-2582.
Wang Z, Canagarajah BJ, Boehm JC, Kassis  S, Cobb 
MH, Young PR, Abdel-Meguid S, Adams JL and 
Goldsmith EJ. Structural basis of inhibitor selectivity 
(28)
(29)
(30)
(31)
(32)
(33)
(34)
in MAP kinases. Structure. (1998) 6: 1117-1128.
Humphrey W, Dalke A and Schulten K. VMD: visual 
molecular dynamics. J. Mol. Graphics. (1996) 14: 
33-38.
Levine IN (2008) Physical chemistry. McGraw-Hill, 
Dougherty DA. Cation-π Interactions in Chemistry and 
Biology: A New View of Benzene, Phe, Tyr, and Trp. 
Sci. (1996) 271: 163-168.
Ma JC and Dougherty DA. The cation-pi interaction. 
Chem. Rev. (1997) 97: 1303-1324.
(38) Gallivan JP and Dougherty DA. A Computational 
Study of Cation-pi Interactions vs. Salt Bridges in 
Aqueous Media: Implications for Protein Engineering. 
J. Am. Chem. Soc. (2000) 122: 870-874.
Gill AL, Verdonk M, Boyle RG and Taylor R. A 
comparison of physicochemical property profiles of 
marketed oral drugs and orally bioavailable anti-cancer 
protein kinase inhibitors in clinical development. Curr. 
Top. Med. Chem. (2007) 7: 1408-1422.
Mulliken R. Electronic Population Analysis on LCAO 
MO Molecular Wave Functions. IV. Bonding and 
Antibonding in LCAO and Valence Bond Theories. J. 
Chem. Phys. (1955) 23: 2343-2346.
(35)
(36)
(37)
(38)
(39)
(40)
or
 http:// ijpr.sbmu.ac.ir
Search full text articles? 
Visit http://www.ijpr.ir
Journal alert and more ...
Visit http://www.ijpr.ir
or
 http:// ijpr.sbmu.ac.ir
